Trials / Terminated
TerminatedNCT01524406
Safety Study of HPP593 in Subjects During and After Limb Immobilization
A Randomized, Double-blind, Placebo Controlled, Phase I Study to Evaluate the Safety and Tolerability of 28 Day Treatment With HPP593 Capsules in Healthy Volunteers During and After Limb Immobilization
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- High Point Pharmaceuticals, LLC. · Industry
- Sex
- Male
- Age
- 30 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a safety and tolerability study investigating the effect of HPP593 in healthy volunteers during and after limb immobilization.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HPP593 | Oral, twice a day. |
| DRUG | Placebo | Oral, twice a day. |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2013-06-01
- Completion
- 2013-06-01
- First posted
- 2012-02-02
- Last updated
- 2014-07-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01524406. Inclusion in this directory is not an endorsement.